Drug Shortage Report for NAT-ERIBULIN
| Report ID | 265770 |
| Drug Identification Number | 02539136 |
| Brand name | NAT-ERIBULIN |
| Common or Proper name | ERIBULIN |
| Company Name | NATCO PHARMA (CANADA) INC |
| Market Status | MARKETED |
| Active Ingredient(s) | ERIBULIN MESYLATE |
| Strength(s) | 0.5MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS |
| Packaging size | 1 VIAL |
| ATC code | L01XX |
| ATC description | OTHER ANTINEOPLASTIC AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2025-08-21 |
| Estimated end date | 2026-12-31 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2025-08-22 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 2000 ARGENTIA ROAD, PLAZA 1, SUITE 200 MISSISSAUGA, ONTARIO CANADA L5N 1P7 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2025-08-22 | English | Compare |
| v2 | 2025-08-21 | French | Compare |
| v1 | 2025-08-21 | English | Compare |
Showing 1 to 3 of 3